Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel Disease

Glynis Byrne, Greg Rosenfeld, Yvette Leung, Hong Qian, Julia Raudzus, Carlos Nunez, Brian Bressler, Glynis Byrne, Greg Rosenfeld, Yvette Leung, Hong Qian, Julia Raudzus, Carlos Nunez, Brian Bressler

Abstract

Background: Inflammatory bowel disease (IBD) patients are not routinely screened for depression and anxiety despite knowledge of an increased prevalence in people with chronic disease and negative effects on quality of life.

Methods: Prevalence of anxiety and depression was assessed in IBD outpatients through retrospective chart review. The presence of anxiety and/or depression was determined using the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 self-report questionnaires or by diagnosis through psychiatric interview. Patient demographics, disease characteristics, and medication information were also collected. Multivariable analysis was used to determine associations between patient factors and depression and anxiety.

Results: 327 patient charts were reviewed. Rates of depression and anxiety were found to be 25.8% and 21.2%, with 30.3% of patients suffering from depression and/or anxiety. Disease activity was found to be significantly associated with depression and/or anxiety (p = 0.01). Females were more likely to have anxiety (p = 0.01).

Conclusion: A significant proportion of IBD patients suffer from depression and/or anxiety. The rates of these mental illnesses would justify screening and referral for psychiatric treatment in clinics treating this population. Patients with active disease are particularly at risk for anxiety and depression.

Figures

Figure 1
Figure 1
Percentage of patients found to have anxiety and/or depression at present with active and inactive disease. Error bars represent 95% CI.

References

    1. Clarke D. M., Currie K. C. Depression, anxiety and their relationship with chronic diseases: A review of the epidemiology, risk and treatment evidence. Med. J. Aust. 2009;190(7):S54–S60.
    1. Patten S. B. Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. Journal of Affective Disorders. 2001;63(1-3):35–41. doi: 10.1016/S0165-0327(00)00186-5.
    1. Graff L. A., Walker J. R., Bernstein C. N. Depression and anxiety in iflammatory bowel disease: a review of comorbidity and management. Inflammatory Bowel Diseases. 2009;15(7):1105–1118. doi: 10.1002/ibd.20873.
    1. Zhang C. K., Hewett J., Hemming J., et al. The influence of depression on quality of life in patients with inflammatory bowel disease. Inflammatory Bowel Diseases. 2013;19(8):1732–1739. doi: 10.1097/mib.0b013e318281f395.
    1. Dimatteo M. R., Lepper H. S., Croghan T. W. Depression is a risk factor for noncompliance with medical treatment meta-analysis of the effects of anxiety and depression on patient adherence. JAMA Internal Medicine. 2000;160(14):2101–2107. doi: 10.1001/archinte.160.14.2101.
    1. Nigro G., Angelini G., Grosso S. B., Caula G., Sategna-Guidetti C. Psychiatric predictors of noncompliance in inflammatory bowel disease: Psychiatry and compliance. Journal of Clinical Gastroenterology. 2001;32(1):66–68. doi: 10.1097/00004836-200101000-00015.
    1. Katon W. J. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin. Neurosci. 2011;13(1):7–23.
    1. Fuller-Thomson E., Sulman J. Depression and inflammatory bowel disease: Findings from two nationally representative Canadian surveys. Inflammatory Bowel Diseases. 2006;12(8):697–707. doi: 10.1097/00054725-200608000-00005.
    1. Spitzer R. L., Kroenke K., Williams J. B. W., Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. JAMA Internal Medicine. 2006;166(10):1092–1097. doi: 10.1001/archinte.166.10.1092.
    1. Kroenke K., Spitzer R. L., Williams J. B. W. The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine. 2001;16(9):606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., Dobos G. J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. American Journal of Gastroenterology. 2008;103(1):162–169. doi: 10.1111/j.1572-0241.2007.01556.x.
    1. Nagy F., Molnár T., Farkas K., et al. P436 Clinical course of ulcerative colitis according to the partial Mayo score based classification during two-year follow-up period: Result from a Hungarian multicenter IBD database. Journal of Crohn's and Colitis. 2012;6:p. S183. doi: 10.1016/S1873-9946(12)60455-3.
    1. Peyrin-Biroulet L., Panés J., Sandborn W. J., et al. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology. 2016;14(3):348–354.e17. doi: 10.1016/j.cgh.2015.06.001.
    1. Pearson C., Janz T., Ali J. Health at a glance mental and substance use disorders in Canada. Stat. Canada. 2013;no. 82:1–8.
    1. Addolorato G., Capristo E., Stefanini G. F., Gasbarrini G. Inflammatory bowel disease: A study of the association between anxiety and depression, physical morbidity, and nutritional status. Scandinavian Journal of Gastroenterology. 1997;32(10):1013–1021. doi: 10.3109/00365529709011218.
    1. Goodhand J. R., Wahed M., Mawdsley J. E., Farmer A. D., Aziz Q., Rampton D. S. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflammatory Bowel Diseases. 2012;18(12):2301–2309. doi: 10.1002/ibd.22916.
    1. Häuser W., Janke K.-H., Klump B., Hinz A. Anxiety and depression in patients with inflammatory bowel disease: Comparisons with chronic liver disease patients and the general population. Inflammatory Bowel Diseases. 2011;17(2):621–632. doi: 10.1002/ibd.21346.
    1. Fuller-Thomson E., Lateef R., Sulman J. Robust Association between Inflammatory Bowel Disease and Generalized Anxiety Disorder: Findings from a Nationally Representative Canadian Study. Inflammatory Bowel Diseases. 2015;21(10):2341–2348. doi: 10.1097/MIB.0000000000000518.
    1. Walker J. R., Ediger J. P., Graff L. A., et al. The Manitoba IBD Cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. American Journal of Gastroenterology. 2008;103(8):1989–1997. doi: 10.1111/j.1572-0241.2008.01980.x.
    1. Korkeila K., Suominen S., Ahvenainen J., et al. Non-response and related factors in a nation-wide health survey. European Journal of Epidemiology. 2001;17(11):991–999. doi: 10.1023/A:1020016922473.
    1. Janzon L., Hanson B. S., Isacsson S.-O., Lindell S. E., Steen B. Factors influencing participation in health surveys. Results from prospective population study 'Men born in 1914' in Malmo, Sweden. Journal of Epidemiology and Community Health. 1986;40(2):174–177. doi: 10.1136/jech.40.2.174.
    1. Nahon S., Lahmek P., Durance C., et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflammatory Bowel Diseases. 2012;18(11):2086–2091. doi: 10.1002/ibd.22888.
    1. McLean C. P., Asnaani A., Litz B. T., Hofmann S. G. Gender differences in anxiety disorders: Prevalence, course of illness, comorbidity and burden of illness. Journal of Psychiatric Research. 2011;45(8):1027–1035. doi: 10.1016/j.jpsychires.2011.03.006.
    1. Andrews H., Barczak P., Allan R. N. Psychiatric illness in patients with inflammatory bowel disease. Gut. 1987;28(12):1600–1604. doi: 10.1136/gut.28.12.1600.
    1. Lopez-Sanroman A., Bermejo F. Review article: How to control and improve adherence to therapy in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2006;24(3):45–49. doi: 10.1111/j.1365-2036.2006.03060.x.
    1. Guthrie E., Jackson J., Shaffer J., Thompson D., Tomenson B., Creed F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. American Journal of Gastroenterology. 2002;97(8):2–7. doi: 10.1111/j.1572-0241.2002.05842.x.
    1. Limsrivilai J., Stidham R. W., Govani S. M., Waljee A. K., Huang W., Higgins P. D. R. Factors That Predict High Health Care Utilization and Costs for Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology. 2017;15(3):385–392. doi: 10.1016/j.cgh.2016.09.012.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren